A systematic review and meta-analysis of pazopanib efficacy and adverse effects in sarcomas
J Transl Med. 2026 Feb 2. doi: 10.1186/s12967-026-07775-1. Online ahead of print.ABSTRACTBACKGROUND: Pazopanib, a multi-targeted tyrosine kinase inhibitor, is employed in the treatment of various malignancies, including metastatic non-adipocytic soft tissue sarcoma.METHODS: This systematic review an

